nodes	percent_of_prediction	percent_of_DWPC	metapath
Dipivefrin—ACHE—prostate cancer	0.544	0.664	CbGaD
Dipivefrin—ADRB2—prostate cancer	0.275	0.336	CbGaD
Dipivefrin—Bambuterol—ADRB2—prostate cancer	0.00259	0.607	CrCbGaD
Dipivefrin—ACHE—prostate gland—prostate cancer	0.00157	0.124	CbGeAlD
Dipivefrin—Arrhythmia—Abiraterone—prostate cancer	0.00148	0.0358	CcSEcCtD
Dipivefrin—Conjunctivitis—Cabazitaxel—prostate cancer	0.00138	0.0333	CcSEcCtD
Dipivefrin—Hypertension—Abiraterone—prostate cancer	0.00125	0.0301	CcSEcCtD
Dipivefrin—Arrhythmia—Degarelix—prostate cancer	0.00121	0.0292	CcSEcCtD
Dipivefrin—Conjunctivitis—Bicalutamide—prostate cancer	0.00119	0.0286	CcSEcCtD
Dipivefrin—Arrhythmia—Cabazitaxel—prostate cancer	0.00114	0.0275	CcSEcCtD
Dipivefrin—Hypertension—Nilutamide—prostate cancer	0.00114	0.0275	CcSEcCtD
Dipivefrin—Hypertension—Flutamide—prostate cancer	0.00114	0.0274	CcSEcCtD
Dipivefrin—Hypertension—Degarelix—prostate cancer	0.00102	0.0246	CcSEcCtD
Dipivefrin—Pain—Estrone—prostate cancer	0.000992	0.0239	CcSEcCtD
Dipivefrin—Arrhythmia—Bicalutamide—prostate cancer	0.000978	0.0236	CcSEcCtD
Dipivefrin—Hypertension—Cabazitaxel—prostate cancer	0.00096	0.0231	CcSEcCtD
Dipivefrin—Pain—Nilutamide—prostate cancer	0.000922	0.0222	CcSEcCtD
Dipivefrin—Tachycardia—Cabazitaxel—prostate cancer	0.000885	0.0213	CcSEcCtD
Dipivefrin—Pain—Estradiol valerate/Dienogest—prostate cancer	0.000866	0.0209	CcSEcCtD
Dipivefrin—ADRA1A—prostate gland—prostate cancer	0.000865	0.0683	CbGeAlD
Dipivefrin—Epinephrine—SLC22A1—prostate cancer	0.000842	0.198	CrCbGaD
Dipivefrin—ADRA2C—prostate gland—prostate cancer	0.000825	0.0651	CbGeAlD
Dipivefrin—Pain—Degarelix—prostate cancer	0.000823	0.0199	CcSEcCtD
Dipivefrin—Hypertension—Bicalutamide—prostate cancer	0.000823	0.0198	CcSEcCtD
Dipivefrin—Pain—Cabazitaxel—prostate cancer	0.000776	0.0187	CcSEcCtD
Dipivefrin—BCHE—prostate gland—prostate cancer	0.000769	0.0607	CbGeAlD
Dipivefrin—Hypersensitivity—Estradiol valerate/Dienogest—prostate cancer	0.000746	0.018	CcSEcCtD
Dipivefrin—Hypersensitivity—Degarelix—prostate cancer	0.000709	0.0171	CcSEcCtD
Dipivefrin—ADRA2C—seminal vesicle—prostate cancer	0.000697	0.0551	CbGeAlD
Dipivefrin—ACHE—testis—prostate cancer	0.000689	0.0544	CbGeAlD
Dipivefrin—Arrhythmia—Goserelin—prostate cancer	0.000681	0.0164	CcSEcCtD
Dipivefrin—Arrhythmia—Conjugated Estrogens—prostate cancer	0.000674	0.0163	CcSEcCtD
Dipivefrin—Hypersensitivity—Cabazitaxel—prostate cancer	0.000668	0.0161	CcSEcCtD
Dipivefrin—Pain—Bicalutamide—prostate cancer	0.000665	0.016	CcSEcCtD
Dipivefrin—ADRA2A—prostate gland—prostate cancer	0.000658	0.0519	CbGeAlD
Dipivefrin—Conjunctivitis—Estradiol—prostate cancer	0.000654	0.0158	CcSEcCtD
Dipivefrin—BCHE—seminal vesicle—prostate cancer	0.000651	0.0514	CbGeAlD
Dipivefrin—Stinging—Epirubicin—prostate cancer	0.000645	0.0155	CcSEcCtD
Dipivefrin—ADRA1A—epithelium—prostate cancer	0.000636	0.0502	CbGeAlD
Dipivefrin—Conjunctivitis—Mitoxantrone—prostate cancer	0.000609	0.0147	CcSEcCtD
Dipivefrin—Stinging—Doxorubicin—prostate cancer	0.000597	0.0144	CcSEcCtD
Dipivefrin—ADRA1A—renal system—prostate cancer	0.00059	0.0466	CbGeAlD
Dipivefrin—Hypersensitivity—Bicalutamide—prostate cancer	0.000573	0.0138	CcSEcCtD
Dipivefrin—Hypertension—Goserelin—prostate cancer	0.000573	0.0138	CcSEcCtD
Dipivefrin—ADRA2C—renal system—prostate cancer	0.000562	0.0444	CbGeAlD
Dipivefrin—ADRA2A—seminal vesicle—prostate cancer	0.000556	0.0439	CbGeAlD
Dipivefrin—ADRA2C—urethra—prostate cancer	0.000552	0.0436	CbGeAlD
Dipivefrin—Epinephrine—ADRB2—prostate cancer	0.000537	0.126	CrCbGaD
Dipivefrin—Tachycardia—Goserelin—prostate cancer	0.000528	0.0127	CcSEcCtD
Dipivefrin—Tachycardia—Conjugated Estrogens—prostate cancer	0.000523	0.0126	CcSEcCtD
Dipivefrin—Arrhythmia—Mitoxantrone—prostate cancer	0.000503	0.0121	CcSEcCtD
Dipivefrin—ACHE—lymph node—prostate cancer	0.0005	0.0395	CbGeAlD
Dipivefrin—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.000485	0.0117	CcSEcCtD
Dipivefrin—Pain—Goserelin—prostate cancer	0.000463	0.0112	CcSEcCtD
Dipivefrin—Pain—Conjugated Estrogens—prostate cancer	0.000458	0.0111	CcSEcCtD
Dipivefrin—Hypertension—Estradiol—prostate cancer	0.000454	0.0109	CcSEcCtD
Dipivefrin—ADRA2A—urethra—prostate cancer	0.000441	0.0348	CbGeAlD
Dipivefrin—Hypertension—Mitoxantrone—prostate cancer	0.000423	0.0102	CcSEcCtD
Dipivefrin—Conjunctivitis—Docetaxel—prostate cancer	0.000421	0.0102	CcSEcCtD
Dipivefrin—Tachycardia—Estradiol—prostate cancer	0.000419	0.0101	CcSEcCtD
Dipivefrin—Conjunctivitis—Capecitabine—prostate cancer	0.000408	0.00983	CcSEcCtD
Dipivefrin—Hypersensitivity—Goserelin—prostate cancer	0.000399	0.00961	CcSEcCtD
Dipivefrin—BCHE—bone marrow—prostate cancer	0.000396	0.0313	CbGeAlD
Dipivefrin—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000395	0.00952	CcSEcCtD
Dipivefrin—Tachycardia—Mitoxantrone—prostate cancer	0.00039	0.00941	CcSEcCtD
Dipivefrin—Pain—Estradiol—prostate cancer	0.000367	0.00885	CcSEcCtD
Dipivefrin—ADRA2C—testis—prostate cancer	0.000363	0.0287	CbGeAlD
Dipivefrin—Hypertension—Etoposide—prostate cancer	0.000352	0.00848	CcSEcCtD
Dipivefrin—Arrhythmia—Docetaxel—prostate cancer	0.000348	0.00838	CcSEcCtD
Dipivefrin—Pain—Mitoxantrone—prostate cancer	0.000342	0.00824	CcSEcCtD
Dipivefrin—BCHE—testis—prostate cancer	0.000339	0.0268	CbGeAlD
Dipivefrin—Arrhythmia—Capecitabine—prostate cancer	0.000336	0.00811	CcSEcCtD
Dipivefrin—Tachycardia—Etoposide—prostate cancer	0.000325	0.00783	CcSEcCtD
Dipivefrin—Hypersensitivity—Estradiol—prostate cancer	0.000316	0.00762	CcSEcCtD
Dipivefrin—Arrhythmia—Prednisone—prostate cancer	0.0003	0.00723	CcSEcCtD
Dipivefrin—Hypersensitivity—Mitoxantrone—prostate cancer	0.000295	0.0071	CcSEcCtD
Dipivefrin—Epinephrine—CYP3A4—prostate cancer	0.000294	0.069	CrCbGaD
Dipivefrin—Hypertension—Docetaxel—prostate cancer	0.000292	0.00705	CcSEcCtD
Dipivefrin—ADRA2A—testis—prostate cancer	0.00029	0.0229	CbGeAlD
Dipivefrin—Pain—Etoposide—prostate cancer	0.000284	0.00686	CcSEcCtD
Dipivefrin—Conjunctivitis—Epirubicin—prostate cancer	0.000284	0.00685	CcSEcCtD
Dipivefrin—Hypertension—Capecitabine—prostate cancer	0.000283	0.00682	CcSEcCtD
Dipivefrin—Tachycardia—Docetaxel—prostate cancer	0.00027	0.0065	CcSEcCtD
Dipivefrin—ADRA2C—lymph node—prostate cancer	0.000263	0.0208	CbGeAlD
Dipivefrin—Conjunctivitis—Doxorubicin—prostate cancer	0.000263	0.00634	CcSEcCtD
Dipivefrin—Tachycardia—Capecitabine—prostate cancer	0.000261	0.0063	CcSEcCtD
Dipivefrin—Hypertension—Prednisone—prostate cancer	0.000252	0.00608	CcSEcCtD
Dipivefrin—BCHE—lymph node—prostate cancer	0.000246	0.0194	CbGeAlD
Dipivefrin—Hypersensitivity—Etoposide—prostate cancer	0.000245	0.00591	CcSEcCtD
Dipivefrin—Pain—Docetaxel—prostate cancer	0.000236	0.0057	CcSEcCtD
Dipivefrin—Arrhythmia—Epirubicin—prostate cancer	0.000234	0.00565	CcSEcCtD
Dipivefrin—Tachycardia—Prednisone—prostate cancer	0.000233	0.00561	CcSEcCtD
Dipivefrin—Pain—Capecitabine—prostate cancer	0.000229	0.00552	CcSEcCtD
Dipivefrin—Arrhythmia—Doxorubicin—prostate cancer	0.000217	0.00523	CcSEcCtD
Dipivefrin—ADRA2A—lymph node—prostate cancer	0.00021	0.0166	CbGeAlD
Dipivefrin—Hypersensitivity—Docetaxel—prostate cancer	0.000204	0.00491	CcSEcCtD
Dipivefrin—Hypertension—Epirubicin—prostate cancer	0.000197	0.00475	CcSEcCtD
Dipivefrin—Hypersensitivity—Capecitabine—prostate cancer	0.000197	0.00475	CcSEcCtD
Dipivefrin—Hypertension—Doxorubicin—prostate cancer	0.000182	0.0044	CcSEcCtD
Dipivefrin—Tachycardia—Epirubicin—prostate cancer	0.000182	0.00439	CcSEcCtD
Dipivefrin—Hypersensitivity—Prednisone—prostate cancer	0.000176	0.00423	CcSEcCtD
Dipivefrin—Tachycardia—Doxorubicin—prostate cancer	0.000168	0.00406	CcSEcCtD
Dipivefrin—Pain—Epirubicin—prostate cancer	0.000159	0.00384	CcSEcCtD
Dipivefrin—Pain—Doxorubicin—prostate cancer	0.000148	0.00356	CcSEcCtD
Dipivefrin—Hypersensitivity—Epirubicin—prostate cancer	0.000137	0.00331	CcSEcCtD
Dipivefrin—Hypersensitivity—Doxorubicin—prostate cancer	0.000127	0.00306	CcSEcCtD
Dipivefrin—ADRA2B—Signaling Pathways—CREBBP—prostate cancer	7.31e-06	5.96e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—HIF1A—prostate cancer	7.31e-06	5.96e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—EGF—prostate cancer	7.28e-06	5.94e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—IRS1—prostate cancer	7.28e-06	5.94e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—IGF1—prostate cancer	7.22e-06	5.89e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CREBBP—prostate cancer	7.22e-06	5.89e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—EGFR—prostate cancer	7.18e-06	5.86e-05	CbGpPWpGaD
Dipivefrin—ACHE—Metabolism—EP300—prostate cancer	7.18e-06	5.85e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PIK3CG—prostate cancer	7.15e-06	5.84e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—LEP—prostate cancer	7.13e-06	5.82e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—IGF1—prostate cancer	7.13e-06	5.81e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—IL2—prostate cancer	7.12e-06	5.81e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—TERT—prostate cancer	7.1e-06	5.79e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—EGFR—prostate cancer	7.09e-06	5.79e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CAV1—prostate cancer	7.07e-06	5.77e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—GSK3B—prostate cancer	7.07e-06	5.77e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—KDR—prostate cancer	6.99e-06	5.7e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—MAP2K1—prostate cancer	6.98e-06	5.69e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—INS—prostate cancer	6.97e-06	5.69e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—PIK3CD—prostate cancer	6.93e-06	5.65e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—MAP2K1—prostate cancer	6.89e-06	5.62e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR downstream signaling—PIK3CA—prostate cancer	6.86e-06	5.6e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—SERPINE1—prostate cancer	6.85e-06	5.59e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—PIK3CD—prostate cancer	6.84e-06	5.58e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CREBBP—prostate cancer	6.83e-06	5.57e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—ESR1—prostate cancer	6.81e-06	5.56e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—HIF1A—prostate cancer	6.79e-06	5.54e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—KRAS—prostate cancer	6.78e-06	5.54e-05	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR downstream signaling—PIK3CA—prostate cancer	6.78e-06	5.53e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—INS—prostate cancer	6.77e-06	5.52e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—SERPINE1—prostate cancer	6.77e-06	5.52e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—PIK3CB—prostate cancer	6.75e-06	5.51e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—IGF1—prostate cancer	6.74e-06	5.5e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Hemostasis—AKT1—prostate cancer	6.73e-06	5.49e-05	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—PTEN—prostate cancer	6.71e-06	5.48e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—EGFR—prostate cancer	6.71e-06	5.47e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—KRAS—prostate cancer	6.7e-06	5.47e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—PTGS2—prostate cancer	6.69e-06	5.46e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—BAD—prostate cancer	6.65e-06	5.42e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—FGF2—prostate cancer	6.64e-06	5.41e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—CREBBP—prostate cancer	6.63e-06	5.41e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—LEP—prostate cancer	6.63e-06	5.41e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CAV1—prostate cancer	6.57e-06	5.36e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—FGF2—prostate cancer	6.55e-06	5.35e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—NOS3—prostate cancer	6.54e-06	5.34e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—MAP2K1—prostate cancer	6.52e-06	5.32e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—KDR—prostate cancer	6.49e-06	5.3e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—PIK3CD—prostate cancer	6.47e-06	5.28e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—NOS3—prostate cancer	6.46e-06	5.27e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—PIK3CG—prostate cancer	6.44e-06	5.25e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—APC—prostate cancer	6.44e-06	5.25e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR downstream signaling—PIK3CA—prostate cancer	6.41e-06	5.23e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—SERPINE1—prostate cancer	6.4e-06	5.22e-05	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—EP300—prostate cancer	6.4e-06	5.22e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—IRS1—prostate cancer	6.36e-06	5.19e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—EGF—prostate cancer	6.36e-06	5.19e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—JAK2—prostate cancer	6.36e-06	5.19e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—KRAS—prostate cancer	6.34e-06	5.17e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—ESR1—prostate cancer	6.33e-06	5.16e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PIK3CD—prostate cancer	6.29e-06	5.13e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—JAK2—prostate cancer	6.28e-06	5.12e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—PIK3CA—prostate cancer	6.23e-06	5.09e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—MDM2—prostate cancer	6.21e-06	5.07e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—FGF2—prostate cancer	6.2e-06	5.06e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—GSK3B—prostate cancer	6.18e-06	5.04e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—BAD—prostate cancer	6.18e-06	5.04e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—PIK3CA—prostate cancer	6.15e-06	5.02e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—MDM2—prostate cancer	6.13e-06	5e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—ERBB2—prostate cancer	6.12e-06	4.99e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—NOS3—prostate cancer	6.11e-06	4.99e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—INS—prostate cancer	6.09e-06	4.97e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—ERBB2—prostate cancer	6.04e-06	4.93e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—PIK3CB—prostate cancer	6.04e-06	4.93e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PIK3CG—prostate cancer	5.98e-06	4.88e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—APC—prostate cancer	5.98e-06	4.88e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CREBBP—prostate cancer	5.97e-06	4.87e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—PIK3CB—prostate cancer	5.96e-06	4.87e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—JAK2—prostate cancer	5.94e-06	4.85e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—NOS3—prostate cancer	5.94e-06	4.85e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—IRS1—prostate cancer	5.91e-06	4.82e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—EGF—prostate cancer	5.91e-06	4.82e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—IGF1—prostate cancer	5.89e-06	4.81e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—EGFR—prostate cancer	5.86e-06	4.79e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—PTEN—prostate cancer	5.83e-06	4.76e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—PIK3CA—prostate cancer	5.82e-06	4.75e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CXCL8—prostate cancer	5.8e-06	4.74e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—MDM2—prostate cancer	5.8e-06	4.73e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—GSK3B—prostate cancer	5.74e-06	4.68e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CXCL8—prostate cancer	5.73e-06	4.68e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—ERBB2—prostate cancer	5.72e-06	4.67e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—MAP2K1—prostate cancer	5.7e-06	4.65e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CDKN1B—prostate cancer	5.67e-06	4.63e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—INS—prostate cancer	5.66e-06	4.62e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—PIK3CD—prostate cancer	5.66e-06	4.62e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—PIK3CB—prostate cancer	5.64e-06	4.6e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR downstream signaling—AKT1—prostate cancer	5.61e-06	4.58e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR downstream signaling—PIK3CA—prostate cancer	5.6e-06	4.57e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—SERPINE1—prostate cancer	5.6e-06	4.57e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CDKN1B—prostate cancer	5.6e-06	4.57e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—EP300—prostate cancer	5.56e-06	4.54e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CASP3—prostate cancer	5.56e-06	4.53e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—IL2—prostate cancer	5.55e-06	4.53e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CREBBP—prostate cancer	5.55e-06	4.52e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—KRAS—prostate cancer	5.54e-06	4.52e-05	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR downstream signaling—AKT1—prostate cancer	5.54e-06	4.52e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—IL6—prostate cancer	5.52e-06	4.5e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CASP3—prostate cancer	5.48e-06	4.48e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PIK3CB—prostate cancer	5.48e-06	4.47e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—IL2—prostate cancer	5.48e-06	4.47e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—IGF1—prostate cancer	5.48e-06	4.47e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—IL6—prostate cancer	5.45e-06	4.45e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—EGFR—prostate cancer	5.45e-06	4.45e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PTGS2—prostate cancer	5.43e-06	4.43e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CXCL8—prostate cancer	5.42e-06	4.42e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—FGF2—prostate cancer	5.42e-06	4.42e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CCND1—prostate cancer	5.41e-06	4.41e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CTNNB1—prostate cancer	5.36e-06	4.37e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—NOS3—prostate cancer	5.34e-06	4.36e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CCND1—prostate cancer	5.34e-06	4.36e-05	CbGpPWpGaD
Dipivefrin—ACHE—Metabolism—PIK3CA—prostate cancer	5.31e-06	4.33e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CDKN1B—prostate cancer	5.29e-06	4.32e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—MAP2K1—prostate cancer	5.29e-06	4.32e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	5.29e-06	4.31e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PIK3CD—prostate cancer	5.26e-06	4.29e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—MMP9—prostate cancer	5.25e-06	4.28e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR downstream signaling—AKT1—prostate cancer	5.24e-06	4.27e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—CDKN1A—prostate cancer	5.23e-06	4.27e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—PTEN—prostate cancer	5.22e-06	4.26e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR downstream signaling—PIK3CA—prostate cancer	5.21e-06	4.25e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—SERPINE1—prostate cancer	5.2e-06	4.24e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—JAK2—prostate cancer	5.19e-06	4.24e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CASP3—prostate cancer	5.19e-06	4.23e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—MMP9—prostate cancer	5.18e-06	4.23e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—IL2—prostate cancer	5.18e-06	4.23e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	5.16e-06	4.21e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—IL6—prostate cancer	5.16e-06	4.21e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—PTEN—prostate cancer	5.15e-06	4.2e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—KRAS—prostate cancer	5.15e-06	4.2e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—AKT1—prostate cancer	5.09e-06	4.15e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—PIK3CA—prostate cancer	5.09e-06	4.15e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—MDM2—prostate cancer	5.07e-06	4.14e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CCND1—prostate cancer	5.05e-06	4.12e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—FGF2—prostate cancer	5.03e-06	4.11e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—AKT1—prostate cancer	5.03e-06	4.1e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CTNNB1—prostate cancer	5e-06	4.08e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—ERBB2—prostate cancer	5e-06	4.08e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—EP300—prostate cancer	4.98e-06	4.06e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—NOS3—prostate cancer	4.96e-06	4.05e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—PIK3CB—prostate cancer	4.93e-06	4.02e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—EP300—prostate cancer	4.91e-06	4.01e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—MMP9—prostate cancer	4.9e-06	4e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—CDKN1A—prostate cancer	4.89e-06	3.99e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—PTEN—prostate cancer	4.88e-06	3.98e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—SRC—prostate cancer	4.84e-06	3.95e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—JAK2—prostate cancer	4.83e-06	3.94e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—SRC—prostate cancer	4.78e-06	3.9e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—AKT1—prostate cancer	4.76e-06	3.88e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CXCL8—prostate cancer	4.74e-06	3.87e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PTEN—prostate cancer	4.74e-06	3.86e-05	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—PIK3CA—prostate cancer	4.74e-06	3.86e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	4.73e-06	3.86e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—VEGFA—prostate cancer	4.71e-06	3.85e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—MDM2—prostate cancer	4.71e-06	3.84e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—STAT3—prostate cancer	4.67e-06	3.81e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—VEGFA—prostate cancer	4.65e-06	3.8e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—EP300—prostate cancer	4.65e-06	3.79e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	4.64e-06	3.79e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CDKN1B—prostate cancer	4.63e-06	3.78e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—STAT3—prostate cancer	4.61e-06	3.76e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	4.58e-06	3.74e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR downstream signaling—AKT1—prostate cancer	4.58e-06	3.74e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CASP3—prostate cancer	4.54e-06	3.7e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—IL2—prostate cancer	4.53e-06	3.7e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—SRC—prostate cancer	4.52e-06	3.69e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—EP300—prostate cancer	4.52e-06	3.69e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—IL6—prostate cancer	4.51e-06	3.68e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CCND1—prostate cancer	4.42e-06	3.6e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	4.4e-06	3.59e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—VEGFA—prostate cancer	4.4e-06	3.59e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	4.37e-06	3.57e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—STAT3—prostate cancer	4.36e-06	3.56e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—MYC—prostate cancer	4.34e-06	3.54e-05	CbGpPWpGaD
Dipivefrin—ACHE—Metabolism—AKT1—prostate cancer	4.34e-06	3.54e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—TGFB1—prostate cancer	4.33e-06	3.53e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	4.3e-06	3.51e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—MMP9—prostate cancer	4.29e-06	3.5e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—MYC—prostate cancer	4.28e-06	3.49e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	4.27e-06	3.49e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—TGFB1—prostate cancer	4.27e-06	3.49e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—PTEN—prostate cancer	4.26e-06	3.48e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	4.25e-06	3.47e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—EGFR—prostate cancer	4.24e-06	3.46e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CASP3—prostate cancer	4.22e-06	3.44e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—IL2—prostate cancer	4.21e-06	3.43e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—EGFR—prostate cancer	4.19e-06	3.42e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—IL6—prostate cancer	4.19e-06	3.42e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	4.16e-06	3.39e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—PIK3CA—prostate cancer	4.11e-06	3.36e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CCND1—prostate cancer	4.1e-06	3.35e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—EP300—prostate cancer	4.06e-06	3.32e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	4.06e-06	3.32e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—MYC—prostate cancer	4.05e-06	3.31e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—TGFB1—prostate cancer	4.04e-06	3.3e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—KRAS—prostate cancer	4.01e-06	3.27e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—MMP9—prostate cancer	3.98e-06	3.25e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	3.97e-06	3.24e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—EGFR—prostate cancer	3.96e-06	3.23e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PTEN—prostate cancer	3.96e-06	3.23e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—KRAS—prostate cancer	3.96e-06	3.23e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—SRC—prostate cancer	3.95e-06	3.23e-05	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—AKT1—prostate cancer	3.87e-06	3.16e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	3.86e-06	3.15e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	3.85e-06	3.14e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—STAT3—prostate cancer	3.81e-06	3.11e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—EP300—prostate cancer	3.78e-06	3.08e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—KRAS—prostate cancer	3.74e-06	3.05e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—PIK3CA—prostate cancer	3.68e-06	3e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—SRC—prostate cancer	3.67e-06	3e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	3.64e-06	2.97e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	3.58e-06	2.92e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—TP53—prostate cancer	3.56e-06	2.91e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—MYC—prostate cancer	3.54e-06	2.89e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—STAT3—prostate cancer	3.54e-06	2.89e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	3.53e-06	2.88e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—TP53—prostate cancer	3.52e-06	2.87e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—EGFR—prostate cancer	3.46e-06	2.83e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—PIK3CA—prostate cancer	3.44e-06	2.81e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—AKT1—prostate cancer	3.36e-06	2.74e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—PIK3CA—prostate cancer	3.34e-06	2.73e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—TP53—prostate cancer	3.33e-06	2.72e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—MYC—prostate cancer	3.29e-06	2.69e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	3.28e-06	2.68e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—KRAS—prostate cancer	3.27e-06	2.67e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—IL6—prostate cancer	3.26e-06	2.66e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—IL6—prostate cancer	3.22e-06	2.63e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—EGFR—prostate cancer	3.22e-06	2.63e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—IL6—prostate cancer	3.05e-06	2.49e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—KRAS—prostate cancer	3.04e-06	2.48e-05	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—AKT1—prostate cancer	3.01e-06	2.45e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	3.01e-06	2.45e-05	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—AKT1—prostate cancer	2.97e-06	2.42e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—TP53—prostate cancer	2.91e-06	2.37e-05	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—AKT1—prostate cancer	2.81e-06	2.29e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	2.79e-06	2.28e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—AKT1—prostate cancer	2.73e-06	2.23e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—TP53—prostate cancer	2.7e-06	2.21e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—IL6—prostate cancer	2.66e-06	2.17e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—IL6—prostate cancer	2.47e-06	2.02e-05	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—AKT1—prostate cancer	2.46e-06	2e-05	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—AKT1—prostate cancer	2.28e-06	1.86e-05	CbGpPWpGaD
